↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Odyssey Therapeutics$ODTX · filed: 🫧 Edgar looked up Odyssey TherapeuticsCheck ▾Close ▴
What Odyssey Therapeutics filed
🫧 Edgar looked up Odyssey Therapeutics, Inc. ($ODTX). Last filing: 10-Q, 2026-11-04. 7 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Odyssey Therapeutics’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Odyssey's **$225M** IPO tests whether autoimmune M&A appetite extends to clinical-stage names in a sector where most 2024 debuts now trade underwater.
$225 million
initial public offering
73%
year-over-year through Q3 2024
$1.8 billion
in US biotech IPOs through September 2024
$6.7 billion
in the prior-year period
Odyssey Therapeutics set pricing terms Monday for a $225 million initial public offering, marking one of the larger US biotech debuts in a sector that saw IPO volume collapse 73% year-over-year through Q3 2024. The Boston-based company, backed by Atlas Venture and Novo Holdings, is pricing this week with three clinical-stage autoimmune programs and no approved products.
The offering comes as biotech IPO windows show selective reopening. Renaissance Capital tracked just $1.8 billion in US biotech IPOs through September 2024, down from $6.7 billion in the prior-year period. Odyssey's decision to price now—rather than wait for January's traditional window—signals either urgent capital needs or conviction that current market conditions represent a local maximum. The company disclosed $180 million in cash as of mid-2024, enough for roughly 18 months at current burn rates, according to S-1 filings.
Odyssey's lead asset, OD-0004, targets IL-13, a cytokine implicated in atopic dermatitis and asthma. The drug entered Phase 2 trials in Q3 2024 with data expected mid-2025. Two earlier-stage programs target undisclosed autoimmune indications, a disclosure choice that limits pre-IPO valuation comparables but protects competitive positioning. The company's scientific founders include former Merck and Bristol Myers executives, a pedigree that matters to crossover funds evaluating management execution risk.
The pricing matters because autoimmune therapeutics saw $47 billion in M&A activity over the past 24 months, with acquirers paying 8x to 12x trailing revenues for late-stage assets. AbbVie's $10.1 billion acquisition of ImmunoGen in November 2023 and Johnson & Johnson's $2 billion purchase of Proteologix in August 2024 established valuation floors for assets with Phase 3 data. Odyssey's clinical-stage positioning means it trades at a discount to those multiples, but the IPO effectively benchmarks investor willingness to fund earlier-stage immunology bets at a time when venture follow-on rounds remain constrained.
Allocators should watch three events. First, OD-0004 Phase 2 interim data in May or June 2025 will determine whether Odyssey can justify its post-IPO valuation or faces a repricing. Second, the company's ability to announce partnerships or out-licensing deals within 90 days post-IPO would signal that strategic acquirers see the pipeline as credible. Third, whether follow-on biotech IPOs price in November and December will clarify if Odyssey's timing was opportunistic or premature.
The offering prices into a market where the iShares Biotechnology ETF is down 4.2% year-to-date, and where 11 of 14 biotech IPOs in 2024 trade below their offer prices. Odyssey's timing depends on investors separating autoimmune exposure from broader sector weakness.
Branded by POPS4 · proof in 60 seconds
For the principal
Watch OD-0004 Phase 2 data in Q2 2025; strategic partnerships within 90 days signal acquisition interest before lock-up expires in six months.
For the operator
Compare Odyssey's post-IPO valuation to ImmunoGen and Proteologix multiples; track crossover fund participation as proxy for institutional confidence in clinical-stage immunology.
For the house
No named-account position pre-IPO; monitor first-day pricing for entry if shares settle 12-18% below offer and Atlas Venture signals follow-on support.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.